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Species of Asarum are used in traditional Chinese medicine and, similar to members of
the genus Aristolochia, they contain aristolochic acid analogs (AAAs). These compounds
are known for their nephrotoxic and carcinogenic effects. So far, the phytochemistry and
nephrotoxicity of species of Asarum is not well studied. A high-resolution LC-MS-based
metabolomic approach was used to study the phytochemical variation in medicinally
used Asarum species. The cytotoxicity of the samples was assessed using human kidney
(HK-2) cells. The majority of samples contained potentially nephrotoxic AAAs, including
9-methoxy aristolactam (AL) IV, AL I, and AL IV. These compounds were present in
methanol as well as water extracts. AAAs were detected in all parts of the plant. The
majority of the extracts were not cytotoxic to HK-2 cells at the doses tested. However,
other mechanisms relating to aristolochic acid nephropathy and cancer development,
such as DNA adduct formation may occur. The results of this study provide a model for
assessing lesser-known plant species for toxicity.
Keywords: metabolomics, LC-MS, nephrotoxicity, Asarum, aristolactam
INTRODUCTION
Species of the genus Asarum are used as herbal medicines in many parts of the world, including
Europe and Asia. The Chinese Pharmacopeia lists the roots and rhizomes of Asarum heteropoides
f. mandshuricum (Maxim.) Kitag, and Asarum sieboldii Miq. under the Pin Yin name Xixin
(Achenbach and Fischer, 1997). In Europe Asarum europaeum L. is used in homeopathic tinctures
(Nitzsche et al., 2013) and in Canada and the USA Asarum canadense L. was used by Native
Americans (Moermon, 2017).
Like the related genus Aristolochia (which is also listed in the Chinese Pharmacopeia),
Asarum contain aristolochic acids and aristolactams (Mix et al., 1982; Kumar et al., 2003). These
nitrophenanthrene derivates have nephrotoxic and carcinogenic effects (Michl et al., 2014). Species
ofAristolochia have become a key concern in healthcare as they are associated with aristolochic acid
nephropathy (AAN), a renal fibrosis often associated with upper urothelial cancer (UUC; Chen
et al., 2012). It is estimated that in China alone 100 million people may be at risk of developing
AAN (Hu et al., 2004; Grollman, 2013).
Species ofAsarum are generally considered to be less toxic than species ofAristolochia. However,
a few cases of Asarum-related AAN have been reported. In one case report a male patient displayed
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subacute renal failure after ingesting a herbal powder containing
Xixin (Yang et al., 2006). A case of acute poisoning due to
the intake of A. europaeum has been reported in Switzerland
(Jaspersen-Schib et al., 1996). Surprisingly, only eight cases of
Asarum-related AANhave been reported in the last 45 years (Kim
et al., 2013). Like Aristolochia-related AAN, it is likely that health
practitioners failed to identify the link between nephropathy or
tumor development and the exposure to these plants.
Aristolochic acid I (AA I) and aristolochic acid II (AA
II) are considered to be the cause of these nephrotoxic and
carcinogenic effects (Nortier et al., 2000; Balachandran et al.,
2005; Jelakovic et al., 2012). After reductive metabolic activation
into aristolactams (ALs), AA I and AA II form DNA adducts,
which were found in renal tissues of patients. A large number
of in vitro and in vivo studies showed that AA I and AA II are
toxic (Mengs, 1988; Arlt et al., 2011; Yang et al., 2011; Michl
et al., 2014). However, they are not necessarily the only (or most
potent) toxins present in Aristolochia and related genera (Michl
et al., 2016). At least 178 aristolochic acid analogs (AAAs) exist,
many of which are aristolactams. It is unclear whether these
compounds are also able to form DNA adducts. Their possible
implications in AAN may have been overlooked (Michl et al.,
2014). Apart from AA I and AA II, other compounds may
contribute to processes that lead to renal damage (Li et al., 2004;
Wen et al., 2006) and carcinogenesis.
Species of Asarum generally contain lower amounts of AA I
and AA II thanAristolochia species (Hashimoto et al., 1999; Chan
et al., 2003, 2006; Yuan et al., 2007). Yet, high amounts of AA I
(3376.9 ng/mg) were reported inAsarum crispulatumC.Y. Cheng
and C.S. Yang (Jong et al., 2003). According to Zhao et al. (2008)
aerial parts of Xixin herbs contained higher levels of AA I than
the roots. Methanol extracts typically contained more AA I than
water extracts. A second study by Hsu et al. (2009) found that the
amounts of AA I in leaves were the highest followed by petioles,
rhizomes and roots.
While a number of studies assessed the amounts of AA I
and AA II in Asarum spp., little is known about the effects of
the entire (small molecule) metabolome and specifically other
AAAs. For example, although other compounds, such as AL I are
often found in higher amounts in Asarum than in Aristolochia
(Yuan et al., 2008), the Chinese Pharmacopoeia still lists roots
and rhizomes of Asarum for medicinal use. Furthermore,
only the decoction of the root portion is recommended for
usage. However, it is questionable as to whether current
recommendations for the medicinal uses of Asarum species are
justified.
The aim of this work is to assess the metabolomic profile
and in vitro toxicity of medicinally used species of Asarum and
to evaluate whether current recommendations for their use are
appropriate. Therefore, we utilized a systems biology approach
to establish the full range of AAAs in a series of Asarum species.
We carried out a LC-MS-based metabolomic study to compare
the secondary metabolites of Asarum samples originating from
different species, different plant parts, as well as obtained through
different extraction techniques. We assessed the cytotoxicity of
these extracts in HK-2 kidney cells and studied the relationship
between the plants’ metabolic profiles and their in vitro toxicity
using statistical approaches. In a wider context, the current work
can be used as a model for assessing toxicity of medicinal plant
species, and for elucidating bioactive principles of medicinal
plants.
MATERIALS AND METHODS
Plant Material
Asarum samples were mainly obtained from commercial sources
in the UK, China, Taiwan or Austria (Table 1). Additional
samples were obtained from the living collection at the Royal
Botanic Gardens (RBG), Kew, UK and at the botanical garden at
Dresden University of Technology (DUoT), Dresden, Germany.
Further plant material from the Economic Botany Collection and
the Chinese Medicinal Plants Authentication Centre (CMPAC)
at RBG, Kew, UK was included in the analysis. When possible,
plant material was identified to the species level. However, if no
flowering parts were present in the sample, the species name
under which the sample was traded is listed in brackets inTable 1.
Fresh plant material from RBG Kew and DUoT was freeze-dried
and stored at room temperature until further analysis. All other
samples were stored at room temperature.
Chemicals
The chemicals used for the LC-DAD-ESI-MS analysis were
methanol, acetonitrile, formic acid (all obtained from Thermo
Fisher Scientific, MA, USA). Reference standards for AA I and
AA II were isolated from Aristolochia repens Mill. AA C was
purchased from Phytolab (Germany). AL I was isolated from
A. sieboldii Miq. The purities of all reference standards were
determined using HPLC.
Extraction of the Plant Material
The dried plant material was ground in a mortar and for each
sample 50mg of dried plant material was extracted with 1mL
of 70% aqueous methanol in an 1.5mL Eppendorf microtube.
After about 14 h extraction at room temperature the extracts
were centrifuged at 6,600 relative centrifugal force (RCF) for
10min. The supernatant liquid was filtered using Whatman 0.45
µm polytetrafluoroethylene (PTFE) filters and 700 µL of the
sample solution were used for LC-DAD-ESI-MS measurements.
The samples 3, 8, and 35 were extracted and analyzed
in triplicate to demonstrate repeatability of the extraction
method.
LC-DAD-ESI-MS Analysis
The analysis was carried out using a Thermo Scientific HRAM
LC-MS system (Thermo Scientific, MA, USA) consisting of an
“Accela” liquid chromatograph with diode array detector and
an “LTQ-Orbitrap XL” hybrid linear ion trap-orbitrap mass
spectrometer. Chromatography was performed on a 150 × 3
mm, 3 µm Phenomenex Luna C18 column using a 400 µL/min
flow rate. The separation was obtained using the following linear
mobile phase gradient: 0 min: 90% A, 0% B, 10% C; 50 min:
0% A, 90% B, 10% C, 55 min: 0% A, 90% B, 10% C, 57 min:
90% A, 0% B, 10% C, 60 min 90% A, 0% B, 10% C (A: water,
B: methanol, C: acetontirile containing 1% formic acid). The
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TABLE 1 | Information about Asarum samples.
No. Accession No. Species* Plant part Origin
1 22795 Xixin (A. sp.) Root/rhizome Austria+
2 22796 Xixin (A. sp.) Root/rhizome Austria+
3 22797 Xixin (A. sp.) Root/rhizome Austria+
4 22798 Xixin (A. sp.) Leaf Austria+
5 22799 Xixin extract (A. sp.) Root/rhizome water extract Austria+
6 22800 Xixin (A. sp., possibly A. sieboldii Miq.) Root/rhizome China+
7 22800 Xixin (A. sp., possibly A. sieboldii Miq.) Leaf China+
8 22801 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt. Var. Mandshuricum (Maxim.) Kitag) Root/rhizome China+
9 22802 Xixin (A. sp., possibly A. sieboldii Miq.) Root/rhizome China+
10 22803 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt. Var. mandshuricum (Maxim.) Kitag.) Root/rhizome China+
11 22805 (1984–4852) A. caulescens Maxim. Leaf LC Kew
12 22806 (1969–18007) A. europaeum L. Leaf LC Kew
13 22807 (1978–2742) A. caudatum Lindl. Leaf LC Kew
14 22808 (170–3809) A. canadense L. Leaf LC Kew
15 22809 (2000–2631) A. splendens (F.Maek.) C. Y. Chen and C. S. Yang Leaf LC Kew
16 22810 Xixin extract (A. sp.) Root/rhizome water extract UK+
17 22811 Xixin extract (A. sp.) Root/rhizome water extract UK+
18 22812 Xixin (A. sp.) Root/rhizome UK+
19 22825 Xixin (A. sp.) root/rhizome UK+
20 22825 Xixin (A. sp.) Leaf UK+
21 22813 Xixin (A. sp.) Stem UK+
22 22813 Xixin (A. sp.) Leaf UK+
23 22814 Xixin (A. sp.) Root/rhizome UK+
24 22815 Xixin (A. sp.) Root/rhizome UK+
25 22815 Xixin (A. sp.) Leaf UK+
26 22816 A. sagittarioides C. F. Liang Leaf Austria
27 20327 Xixin (A. sp., possibly A. sieboldii Miq. Var. seolense Nakai) Root/rhizome Taiwan+
28 20326 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag.) Root/rhizome Taiwan+
29 22817 (EBC 47625) Xixin (A. sp., possibly A. sieboldii Miq.) Root/rhizome EBC Kew+
30 22818 (EBC 45660) Xixin (A. sp., possibly A. sieboldii Miq.) Root/rhizome EBC Kew+
31 22819 (EBC 47604) Xixin (A. sp., possibly A. sieboldii Miq.) Root/rhizome EBC Kew+
32 22820 (EBC 80573) A. heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag. Root/rhizome EBC Kew+
33 22820 (EBC 80574) A. heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag. Root/rhizome EBC Kew+
34 22821 (EBC 81420) Xixin (A. sp.) Root/rhizome EBC Kew+
35 22822 (EBC 81093) A. sieboldii Miq. Root/rhizome EBC Kew+
36 22823 (EBC 81424) A. sieboldii Miq. Leaf EBC Kew+
37 22824 (EBC 81480) Xixin (A. sp.) Leaf EBC Kew+
38 20795 A. cardiophyllum Franch. Leaf DUoT
Samples were obtained as commercial products in China, Taiwan, the UK or Austria, through the Economic Botany Collection (EBC), Royal Botanic Gardens (RBG), Kew, the living
collection (LC), Royal Botanic Gardens, Kew or the LC at Dresden University of Technology (DUoT). *For non-authenticated species, the likely taxon is given in brackets. +Commercial
samples.
injection volume was 5 µL. Ammonia solution was added post
column at a flow rate of 0.1 µL/min. The mass spectrometer was
fitted with an electrospray source (Thermo “Ion Max”) operated
in positive mode at a source voltage of 3.5 kV using sheath and
auxiliary nitrogen flow rates of 60 and 20 units, respectively, and
a capillary temperature of 300◦C. High resolution MS1 scanning
was performed in the orbitrap (m/z 250–2000; resolution 30,000).
Low resolution data dependent MS2 scans were undertaken
in the linear ion trap (isolation width 4 m/z units; collision
energy 35%).
Data Reduction and Multivariate Data
Analysis
Filtering, peak extraction, chromatogram de-convolution and
peak alignment of the high-resolution LC-MS data were
performed automatically using Mzmine 2 (http://mzmine.
sourceforge.net). Peaks between 0 and 50min retention time with
a minimum peak intensity of 50,000 and m/z between 200 and
650 were extracted. Only the 1,000 metabolites with the highest
average peak areas across all samples were used for further data
analysis. This process resulted in a data set consisting of 38
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FIGURE 1 | PCA scores plots based on LC-MS data for all Asarum samples. The samples are labeled according to their sample number (Table 1) and different
symbols were assigned for different plant parts or extraction methods (data normalized to the total raw signal, mean-centered, and pareto scaled).
observations (samples) and 1000 variables (metabolites). Before
PCA, the resulting data set was normalized to the total raw signal.
PCA andOPLS-DAwas carried out on the normalized and pareto
scaled dataset using the software SIMCA P+ (v. 12, Umetrics,
Umea, Sweden).
Metabolite Identification Assignment
For the peaks extracted by Mzmine 2, the ion species (i.e.,
adducts) were determined so as to obtain an experimental
accurate molecular mass. This was then searched against the CRC
Dictionary of Natural Products to identify candidate compounds
having molecular masses within 5 ppm of the experimental value.
AA I, AA II, AA III, AA IIIa, AA IV, AA D, AA IIIa-6-β-D-
glucoside, aristolochin, and AL I were identified by comparison
to reference standards. Further, compounds were identified by
comparing accurate mass data to an in-house database (UCL
School of Pharmacy, London, UK) consisting of 178 AAAs, which
have previously been isolated from natural sources. Putative
assignments for those AAAs were made based on their accurate
mass, retention time, mass fragmentation, and UV spectra.
Cell Culture Conditions
HK-2 cells (American Type Culture Collection, Manassas, VA,
USA) were maintained in Dulbecco’s modified eagle medium
(DMEM, Gibco Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Gibco Invitrogen), 100 U/mL penicillin and 100
µg/mL streptomycin (Gibco Invitrogen). All cells were cultured
in a humidified atmosphere with 5% CO2 at 37
◦C. For routine
cultivation, cells were maintained up to 80% of confluency and
the medium was replaced every 3 days.
Sulphorhodamine B (SRB) Assay
Cytotoxicity assessment of the plant extracts was carried out
using the SRB assay (Houghton et al., 2007). HK-2 cells (104
cells/well) were plated in 96-well plates overnight. Afterwards
the medium was replaced by medium containing the plant
extracts dissolved in dimethyl sulfoxide (DMSO, VWR, Poole,
UK). The cells were treated with plant extracts for 72 h at
concentrations of 0, 12.5, 25, 50 100, and 200 µg/mL. The final
concentration of DMSO in the medium did not exceed 1% v/v.
Afterwards the cells were fixed with 40% trichloroacetic acid
(TCA, Sigma, St. Louis, MO, USA) for at least 1 h. The fixed
cells were washed with deionized water and stained with 0.4%
SRB (Sigma, St. Louis, MO, USA) in 1% acetic acid (Fisher
Scientific, Loughborough, UK) for 30min. Afterwards the cells
were washed with 1% acetic acid to remove excess color. Plates
were dried and then dissolved in 30 mM Tris base (Sigma,
St. Louis, MO, USA). Cell growth was quantitated based on
the amount of SRB measured by a spectrophotometer (Tecan
Infinite M200 plate reader, Tecan, Maennedorf, Switzerland) at
490 nm. Three independent experiments were carried out, each
carried out in technical triplicates. IC50 values were obtained
using the curve fit through non-linear regression function
in GraphPad Prism 6.0 (GraphPad Software, San Diego, CA,
USA). Colchicine (10 µg/mL, Sigma, St. Louis, MO, USA) was
used as a positive control to ensure the performance of the
assay.
RESULTS
Phytochemical Variation in Xixin Samples
Using Non-targeted LD-DAD-ESI-MS
We obtained chromatographic information from the non-
targeted metabolomic analysis of 38 Asarum samples (Table 1)
in positive-ionization mode of high resolution accurate mass
LC-MS (HRAM LC-MS). We preprocessed the information
to extract chromatographic features. Matching features from
different samples were aligned. Normalization and pareto scaling
resulted in the final data set for subsequent statistical analysis.
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To study the variability within the data set, principal
component analysis (PCA) was carried out. A 2-component
PCA model explained 23.6% of the total variance. The PCA
scores plot in Figure 1 shows a clear separation between Asarum
leaf and root material. However, different modes of preparation
(methanolic vs. water extracts) were not differentiated. All leaf
samples, as well as sample 21 [Xixin, A. sp. (stem)] were
clearly separated (left hand side of the plot) from the root
samples. This included the commercial root extracts, which are
generally extracted using water decoction (right hand side of
the plot). Thus, the metabolic profile of Asarum extracts is
largely dependent on the part of the plant used, rather than
genetic variability (species) or extraction method. Samples 11–
14 originate from leaves of different species of Asarum (A.
caulescens, A. europaeum, A. caudatum, and A. canadense) and
have similar metabolite profiles. Since many samples used in
traditional Chinese medicine are only available in the form
of botanical drugs, these were not identified to species level
(Table 1). However, since most of these samples were traded
under the Pin Yin name Xixin, it is likely that they originate from
either A. sieboldii or A. heterotropoides. From the PCA scores
plot, it is evident that the phytochemistries of A. sieboldii and
A. heterotropoides are similar (Figure 1). For example, samples
33 and 35 (A. heterotropoides (root) and A. sieboldii (root),
respectively) are located in close proximity in the scores plot.
The PCA loadings plots were used to identify metabolites
responsible for the differentiation in the PCA analysis
(Figure S1). Samples with positive PC1 scores (such as the
majority of root/rhizome samples) are characterized by a major
metabolite giving m/z at 248.2012 (tR = 40.63 min), assigned
as a protonated molecule from the presence of a confirmatory
sodiated molecule at m/z 270.1831, both of which suggest a
molecular formula of C16H25NO (e.g., calc. for C16H26NO
+
=
m/z 248.2009; 1.2 ppm error). A possible candidate is a mixture
of (2E,4E,8Z,10E)-N-isobutyl-2,4,8,10-dodecatetraenamide
and (2E,4E,8Z,10Z)-N-isobutyl-2,4,8,10-dodecatetraenamide,
which was previously isolated from A. sieboldii (Quang et al.,
2012; Wen et al., 2014), Asarum heterotropoides (Quang
et al., 2012) and Asarum forbesii Maxim (Zhang et al., 2005).
These candidates are supported by major fragments in the
MS/MS spectrum of the protonated molecule at m/z 175.119
(C12H15O
+), 149.1326 (C11H
+
17) and 142.1227 (C8H16NO
+),
which can be rationalized against the structures. Samples
with negative PC1 scores (such as all leaf samples) contain
higher amounts of a compound giving m/z at 277.2164 (tR =
42.76 min). This signal can be assigned to the [M+H]+ ion
from a confirmatory [M+NH4]
+ ion at m/z 294.2430, both
suggesting a molecular formula of C18H28O2 (e.g., calc for
C18H29O
+
2 e = 277.2162; 0.6 ppm error). Possible candidates
for this compound are various octadecatetraenoic acids. The
differentiation of the Asarum samples by PC2 is more complex
(Figure S2). Negative PC2 scores correspond to a metabolite
giving a protonated molecule at m/z 597.1815 (tR = 16.45 min).
This is likely to be 2′,4,4′,6′-tetrahydroxychalcone-2′,4′-di-O-β-
D-glucopyranoside (chalcononaringenin 2′,4′-di-O-glucoside),
a flavonoid previously isolated from Asarum canadense L.
(Iwashina and Kitajima, 2000). This identification was supported
by a match of the MS3 (m/z 597→273) spectrum with the
MS2 (m/z 273) spectrum of chalcononaringenin an in-house
library. Further, supporting this identification is the failure of the
sodiated molecule to lose an aglycone moiety following MS/MS
(suggesting the sugars were substituted at two positions). In
contrast, positive PC2 scores correspond to m/z 277.2164 (tR =
42.76 min; an octadecatetraenoic acid as discussed above) and
m/z 295.2269 (tR = 44.21 min; the protonated molecule of a
hydroxyoctadecatrienoic acid).
Variation in AAAs
In order to study the variation in AAAs content, targeted
metabolite profiling was carried out. Several AAAs (AA I,
AL I, AA IIIa, AA D, AA IIIa 6-O-β-D-glucoside, and
aristolochin) could be identified by comparison to reference
standards. However, tentative assignments based on accurate
mass, retention times, UV maxima, and fragmentation ions
obtained through LC-DAD-ESI-MS analysis were made for other
AAAs (Table 2, Figure 2). Table 2 shows the 16 most commonly
occurring AAAs, which could be identified within the set of
analyzed samples. 9-Methoxy AA IV (or one of its isomers)
was found in the highest average amount across all samples.
However, while this compound was found in large amounts in
species such as A. cardiophyllum, and A. saggitaroides, it was
detected in only a few of the commercial Xixin samples (A. sp.
A. sieboldii and A. heterotropoides). Within the analyzed Xixin
samples, AL I was the most common aristolochic acid analog.
However, a variety of other aristolactams such as AL IV and
its isomer AL VII, as well as AL II and N-β-D-glucoside were
detected. While AA I was only detected in seven samples (4,
14, 15, 21, 23, 32, and 36), AA II was not detected at all. AA I
was found in high amounts in A. canadense and A. splendends.
AA I occurred only as a minor compound within Xixin samples,
with the average amount being higher in aerial parts compared
to roots; but in contrast to previous reports22 these differences
were not statistically significant (p = 0.11). On the other hand,
the amounts of AL I in Xixin root samples were significantly
higher, compared to aerial parts (p = 0.03). This finding has
not previously reported, since AL I was only quantified in a few
studies. Although AL I is a rather non-polar compound and
therefore poorly soluble in water, it was also detected in water
based commercial root decoctions. This suggests that AL I can
be extracted into water when heat is used during the extraction
process, or it could be mediated through the formation of ion-
pairs with other substances in the extracts. Although AA I is more
water soluble than ALI, AA I was not detected in any of the three
root decoction samples.
In vitro Toxicity of Asarum Extracts
The cytotoxicity of the Asarum samples in HK-2 cells was
assessed after treatment for 72 h using the sulphorhodamine B
(SRB) assay (Houghton et al., 2007). Several Asarum extracts
showed cytotoxic effects in HK-2 cells (Table 3). For example,
sample 12 [A. europaeum (leaf)] and sample 18 [Xixin, A.
sp. (root)], exhibited IC50 values of 44.10 and 57.01 µg/mL,
respectively. This is comparable to the cytotoxicity of species
of Aristolochia, which was previously assessed in HK-2 cells.
However, the majority of the tested samples did not reduce
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TABLE 2 | Retention times, UV maxima and fragmentation ions of identified aristolochic acid analogs.
No. Compound Retention
time (min)
[M+H]+
(m/z)
[M+NH4]
+(m/z) Fragmentation ions (m/z)c UV maxima (nm)
1b 9-methoxy aristolactam IV (9-methoxy AL IV) 34.61 354.0975 339, 324, 293, 266 236, 271, 287, 343, 393
2 aristolactam Ia (AL I) 36.36 294.0759 279, 251 236, 291, 328, 391
3b aristolactam IV (AL IV) 36.46 324.0867 309, 280, 266 235, 263, 335, 406
4b aristolactam VII (AL VII) 34.78 324.0867 309, 294, 266 234, 304, 414
5 aristolactam II; N-β-D-glucosideb (AL II;
N-β-D-glucoside)
25.40 426.1192 264, 234, 206 234, 277, 330, 274
6 aristolochic acid Da (AA D) 30.55 375.0821 357, 312, 297, 267 238, 329, 408
7 aristolochic acid Ia (AA I) 36.07 359.0870 342, 324, 298, 296, 281, 268 252, 320, 392
8b aristolactam BII (AL BII) 35.74 280.0972 265, 264, 236, 234 235, 276, 317, 379
9 aristolochic acid IIIaa (AA IIIa) 30.92 345.0713 328, 310, 284, 254 235, 321, 400
10 aristolochina 21.94 537.1352 520, 474, 314, 312 240, 325, 404
11b aristofolin A 24.82 537.1353 474, 358, 312, 297 234, 325, 394
12 aristolochic acid IIIa; 6-O-β-D-glucosidea
(AA IIIa; 6-O-β-D-glucoside)
23.20 507.1252 490, 327, 310, 284, 266 252, 304, 390
13 aristolactam IIb (AL II) 34.86 264.0660 234, 206, 179, 235, 277, 325, 374, 392
14 aristolochic acid Eb (AA E) 31.94 375.0826 358, 312, 297, 267 237, 326, 408
15b 7-methoxy aristolactam IV (7-methoxy AL IV) 35.42 354.0976 324, 293, 295, 266 234, 268, 386
16 aristolactam CIIIb (AL CIII) 25.88 340.1181 308, 280 236, 293, 392
The compounds are sorted by descending average peak areas across all samples.
a Identified by comparison with reference standard.
bTentative assignment based on accurate mass, UV spectra, and mass fragmentation.
cFragmentation ions were extracted from MS2 and MS3 scans.
FIGURE 2 | Heat map comparing relative LC-MS peak areas of identified aristolochic acid analogs. Information about the origin of the samples is given in
Table 1. The compounds (rows) are sorted by descending average peak areas across all samples (a identified by comparison with reference standard; bTentative
assignment based on accurate mass, UV spectra and mass fragmentation).
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TABLE 3 | Cytotoxicity (IC50 values) after treatment of HK-2 cells with
Asarum samples for 72 h.
Sample
No.
Species* Cytotoxicity
IC50[µg/mL]
1 Xixin (A. sp.) >200
2 Xixin (A. sp.) >200
3 Xixin (A. sp.) >200
4 Xixin (A. sp.) >200
5 Xixin extract (A. sp.) >200
6 Xixin (A. sp., possibly A. sieboldii Miq.) >200
7 Xixin (A. sp., possibly A. sieboldii Miq.) >200
8 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt.
Var. Mandshuricum (Maxim.) Kitag)
>200
9 Xixin (A. sp., possibly A. sieboldii Miq.) >200
10 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt.
Var. mandshuricum (Maxim.) Kitag.)
>200
11 A. caulescens Maxim. 156.4
12 A. europaeum L. 44.1
13 A. caudatum Lindl. 140.2
14 A. canadense L. >200
15 A. splendens (F.Maek.) C. Y. Chen and C. S. Yang 95.83
16 Xixin extract (A. sp.) >200
17 Xixin extract (A. sp.) >200
18 Xixin (A. sp.) 57.01
19 Xixin (A. sp.) 83.4
20 Xixin (A. sp.) >200
21 Xixin (A. sp.) >200
22 Xixin (A. sp.) >200
23 Xixin (A. sp.) >200
24 Xixin (A. sp.) 77.35
25 Xixin (A. sp.) >200
26 A. sagittarioides C. F. Liang >200
27 Xixin (A. sp., possibly A. sieboldii Miq. Var. seolense
Nakai)
135
28 Xixin (A. sp., possibly A. heterotropoides Fr. Schmidt var.
mandshuricum (Maxim.) Kitag.)
87.9
29 Xixin (A. sp., possibly A. sieboldii Miq.) 78.75
30 Xixin (A. sp., possibly A. sieboldii Miq.) >200
31 Xixin (A. sp., possibly A. sieboldii Miq.) 95.85
32 A. heterotropoides Fr. Schmidt var. mandshuricum
(Maxim.) Kitag.
>200
33 A. heterotropoides Fr. Schmidt var. mandshuricum
(Maxim.) Kitag.
>200
34 Xixin (A. sp.) 194.5
35 A. sieboldii Miq. >200
36 A. sieboldii Miq. >200
37 Xixin (A. sp.) >200
38 A. cardiophyllum Franch. >200
Cytotoxicity was assessed using the sulphorhodamine B (SRB) assay.
* For non-authenticated species, the likely taxon is given in brackets.
cell viability to fewer than 50% of the solvent control at a
concentration of 200 µg/mL.
The AAAs AA I and AA II are considered to be the main
compounds responsible for the nephrotoxic effects of species of
Aristolochia and Asarum. In order to investigate, whether there
is a link between the amounts of AA I in the samples and their
cytotoxicity in HK-2 cells, univariate regression analysis was
carried out. However, no correlation was found between AA I
peak areas and the extracts IC50 values (R
2
= 0.000). This can be
explained by the fact that only one of the samples containing AA I
[A. splendends (leaf)] exhibited cytotoxicity, while no cytotoxicity
was observed for all other samples with doses up to 200 µg/mL.
To elucidate the possible bioactive principle behind the
cytotoxic effects of the extracts, an untargeted approach was
used, where all detected metabolites were taken into account.
Therefore, we used orthogonal projection to latent structures
(OPLS) regression analysis. In contrast to univariate regression
analysis, where the correlation between only one X and one Y
variable is assessed, OPLS is a method for relating two data
matrices (X and Y) within a linear multivariate model. In this
study, the X matrix consisted of 38 observations (samples) and
1,000 variables (the 1,000 metabolites with the highest average
LC-MS peak areas across all samples). However, the Y matrix
consisted of only one qualitative variable (0 for non-toxic vs. 1
for toxic extracts). In this case, since the Y matrix consists of
discrete values, the method is called OPLS-discriminant analysis
(OPLS-DA). The OPLS-DA loadings plots were used to identify
which metabolites correlate directly or indirectly, significantly
or non-significantly with the Y variable (toxic vs. non-toxic).
OPLS-DA showed that toxic samples contain higher amounts
of metabolites giving m/z at 274.2167, 276.2325, and 252.2324.
Themolecular formulas andMS/MS fragmentations of these ions
are in accordance with them being the protonated molecules
of various alkylamides. Aristolochic acids and ALs were not
found to be important discriminators between toxic vs. non-toxic
samples.
DISCUSSION
Asarum species have been used as medicinal plants in China
and in other parts of the world. However, so far little is known
about their content in aristolochic acids and aristolactams or
their potential kidney toxicity. A comprehensive metabolomic
approach has shown that the majority ofAsarum samples contain
AAAs considered to be nephrotoxic.
In TCM, plants known to contain toxic compounds are often
regarded as safer after preparation of the plant material in a
specific way, or only those plant parts known not to contain
the toxins are used. Furthermore, monographs on species in
national pharmacopeias require time to change and often do
not take into account recent advances in the knowledge about
the chemistry of the species. This could result in misleading
recommendations about the use of some species with potential
hazards for public health. The plant genusAsarum is one example
of this, especially since its true level of usage is poorly known
(e.g., in China and Southern Europe). In addition to changing
guidelines in national pharmacopeias, more awareness needs to
be raised about potential health risks associated with the use
of herbal medicine. This will in time lead to changes in the
traditional practices.
Previous reports have shown that levels of aristolochic
acids were low in decoction of roots and rhizomes of Herba
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Asari (Zhao et al., 2008) thus it was retained in the Chinese
Pharmacopoeia. However, in this study, no significant difference
in the levels of AA I was detected in aerial parts of Asarum spp.
compared to root samples. Relative levels of AL I were found to
be even higher in root samples compared to aerial parts, and AL
I was also detected in root decoctions. Little is known about the
toxicity and carcinogenicity of AL I.
Althoughmost Xixin samples included in this study contained
potentially nephrotoxic AAAs, some samples did not contain
detectable amounts of these compounds. This could indicate that
Xixin samples purchased from markets may not originate from
Asarum sp., and were either misidentified or replaced with other
medicinal plants. The lack of detectable AAAs could also be due
to natural variation (genetic, seasonal or ecological) and requires
further investigation. Most samples were non-cytotoxic to kidney
cells in vitro. Interestingly, no correlation was found between the
amounts of AA I and their toxicity. However, other mechanisms
relating to aristolochic acid nephropathy, such as DNA adduct
formation may occur and deserve further research.
The present study has important implications on whether
and how the genus Asarum should be used medicinally in the
future. In contrast to previous studies, where only AA I and
AA II were taken into account, we detected other AAAs in root
and rhizome samples of Asarum. Since little is known about the
toxicity of these compounds, we cannot conclude that root and
rhizome samples are safe to use. The study also demonstrates that
systematic assessment of a group of species’ metabolomic profile
can provide a basis for a broader assessment of associated risks.
Not only are there other compounds than aristolochic acids that
need to be taken into consideration, but the entire composition
of some of the most active extracts needs to be understood.
The study thus serves as a model for assessing closely related
species used as traditional medicines. More broadly, the strategy
presented here can also be used in identifying new drug leads
from medicinal plants (and fungi).
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